Status:
NOT_YET_RECRUITING
ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies
Lead Sponsor:
University Hospital, Caen
Conditions:
Cardiotoxicity
Heart Failure
Eligibility:
All Genders
18+ years
Brief Summary
Cancer treatments have improved substantially over the past decades, but some effective therapies such as anthracyclines and HER2-targeted agents are associated with severe cardiovascular adverse effe...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Planned follow-up in cardio-oncology clinic as part of a baseline pre-treatment evaluation before a sequence of anthracycline and/or HER2-targeted therapy, according to the 2022 ESC recommendations
- Inclusion regardless of prior exposure to potentially cardiotoxic anticancer therapies or thoracic radiotherapy
Exclusion
- Patients not covered by the French national health insurance system (Sécurité Sociale)
- Patients for whom 12-month follow-up is planned outside the center performing the baseline pre-treatment evaluation
Key Trial Info
Start Date :
November 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 1 2028
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT07191730
Start Date
November 1 2025
End Date
November 1 2028
Last Update
September 25 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.